Last updated: 11/03/2018 12:03:24

The expression of antigens in bone marrow samples from volunteering donors.

GSK study ID
111684
See study documents
Clinicaltrials.gov ID
NCT00706199
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Finalized
Finalized
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Analysis of expression of antigens in bone marrow samples from volunteering donors.
Trial description: Antigen expression levels in bone marrow from volunteering donors will be analyzed. The results of this analysis will be used to establish a clinical test to identify cancer patients who could qualify to receive an investigational treatment being developed by GlaxoSmithKline.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

Number of copies of Wilms’ Tumor 1 (WT1) antigen expression in bone marrow

Timeframe: At Day 0

Number of copies of PRAME (Preferentially expressed in melanoma)antigen expression in bone marrow

Timeframe: At Day 0

Secondary outcomes:
Not applicable
Interventions:
Procedure/surgery: Bone marrow aspiration
Enrollment:
48
Observational study model:
Not applicable
Primary completion date:
2009-23-01
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Cancer
Product
GSK1711805A
Collaborators
Not applicable
Study date(s)
July 2008 to January 2009
Type
Observational
Phase
Not applicable

Participation criteria

Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
Yes
  • Inclusion Criteria:
  • The donor is aged >= 18 years
Inclusion and exclusion criteria
Inclusion criteria:
  • Inclusion Criteria:
  • The donor is aged >= 18 years
  • Written informed consent has been obtained prior to the performance of any specific procedure.
  • The donor has a medical indication for which a bone marrow aspiration is planned.
  • The donor is eligible for a bone marrow aspiration.

Trial location(s)

Location
Status
Contact us
Contact us
Location
GSK Investigational Site
Ottignies, Belgium, 1340
Status
Study Complete
Contact us

Study documents

Scientific result summary
Available language(s): English
Download document(s)

If you wish to request for full study report, please contact - [email protected]

Results overview

Refer to study documents

Recruitment status
Finalized
Actual primary completion date
2009-23-01
Actual study completion date
2009-23-01

Plain language summaries

Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

Additional information about the trial

Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website